Your browser is no longer supported. Please, upgrade your browser.
NOVN Novan, Inc. daily Stock Chart
Novan, Inc.
Index- P/E- EPS (ttm)-2.85 Insider Own2.10% Shs Outstand15.20M Perf Week2.27%
Market Cap82.23M Forward P/E- EPS next Y-5.61 Insider Trans0.00% Shs Float9.26M Perf Month-1.46%
Income-52.00M PEG- EPS next Q-0.56 Inst Own6.20% Short Float4.91% Perf Quarter34.24%
Sales0.80M P/S102.79 EPS this Y-479.50% Inst Trans0.11% Short Ratio3.37 Perf Half Y2.46%
Book/sh0.73 P/B7.41 EPS next Y-126.20% ROA-99.60% Target Price9.67 Perf Year-73.61%
Cash/sh1.26 P/C4.31 EPS next 5Y- ROE-194.60% 52W Range3.52 - 30.90 Perf YTD-79.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-82.49% Beta-
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low53.69% ATR0.42
Employees62 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)55.63 Volatility8.97% 6.89%
OptionableYes Debt/Eq0.68 EPS Q/Q48.20% Profit Margin- Rel Volume0.18 Prev Close5.32
ShortableYes LT Debt/Eq0.68 EarningsNov 10 BMO Payout- Avg Volume134.81K Price5.41
Recom2.30 SMA202.49% SMA505.58% SMA200-15.43% Volume23,644 Change1.69%
Oct-20-17 07:20AM  Corporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide ACCESSWIRE
Oct-18-17 03:25PM  Novan leans on its spinout, Know Bio, to bolster acne drug pipeline American City Business Journals
07:05AM  Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide GlobeNewswire
Oct-13-17 08:35AM  Novan Announces Corporate Update Conference Call and Webcast GlobeNewswire +5.17%
Oct-06-17 01:17AM  Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL GlobeNewswire
Sep-28-17 01:21AM  Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets GlobeNewswire +6.37%
Sep-26-17 03:00PM  Novan adds another former RTP biotech exec to its board American City Business Journals
08:30AM  Machelle Sanders Appointed to Novan Board of Directors GlobeNewswire
Sep-25-17 03:20PM  FDA recommends another trial for Novan treatment American City Business Journals
08:00AM  Novan Conducts Guidance Meeting with FDA on SB204 Development Program GlobeNewswire
Sep-22-17 01:17AM  Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries GlobeNewswire
Sep-20-17 01:17AM  Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) GlobeNewswire
Sep-16-17 10:02AM  Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption GlobeNewswire
Sep-14-17 01:17AM  Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study GlobeNewswire +5.77%
Sep-05-17 01:17AM  Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS GlobeNewswire
Sep-04-17 01:02AM  Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. GlobeNewswire
Aug-30-17 11:06AM  Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice GlobeNewswire +9.96%
Aug-28-17 03:01AM  Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk GlobeNewswire +7.96%
Aug-27-17 05:02AM  Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk GlobeNewswire
Aug-24-17 01:17AM  Novartis appoints Bertrand Bodson as Chief Digital Officer GlobeNewswire
01:12AM  Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor GlobeNewswire
Aug-21-17 01:17AM  Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria GlobeNewswire
Aug-16-17 08:05AM  Novan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors GlobeNewswire
Aug-02-17 03:15PM  Novan's interim CEO outlines future focus American City Business Journals -17.15%
Jul-25-17 04:05PM  Novan Announces Corporate Update Conference Call and Webcast GlobeNewswire
Jul-07-17 03:18PM  As it pushes forward with its acne drug, Novan's cash dwindles to $30 million American City Business Journals
09:05AM  Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology GlobeNewswire
Jun-05-17 09:55AM  Novan makes leadership changes, cuts workforce by 20 percent American City Business Journals
08:30AM  Novan Announces Leadership Adjustments and Business Update GlobeNewswire
May-12-17 02:35PM  Durham's Novan stares at company rightsizing, additional financing American City Business Journals
09:11AM  Novan reports 1Q loss Associated Press
09:05AM  Novan Reports First Quarter 2017 Financial Results GlobeNewswire
May-11-17 01:17AM  Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities GlobeNewswire
May-04-17 01:16AM  Novartis exercises exclusive option agreement with Conatus for the treatment of NASH GlobeNewswire
Apr-28-17 11:31AM  Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) GlobeNewswire
Apr-27-17 09:14AM  Novan Presents Safety Data for SB204 Program GlobeNewswire
09:05AM  Novan Presents Preclinical Data from Inflammatory Skin Diseases Program GlobeNewswire
Apr-26-17 01:16AM  Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma GlobeNewswire
Apr-25-17 01:02AM  Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued GlobeNewswire
Apr-24-17 04:31PM  Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada GlobeNewswire
01:16AM  Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS GlobeNewswire
Apr-18-17 01:12AM  Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL GlobeNewswire
Apr-13-17 07:30AM  Novan Gets Positive Phase II Results Accesswire -5.56%
Apr-12-17 12:21PM  Story Stocks from +20.96%
08:13AM  Novan's stock rockets after positive trial results MarketWatch
06:07AM  Novan Reports Positive Topline Results with SB208 in Phase 2 Trial GlobeNewswire
Apr-06-17 01:17AM  Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications GlobeNewswire
Apr-05-17 12:35PM  Novan continues to recruit, adds dermatology advisory council American City Business Journals
Apr-04-17 09:05AM  Novan Welcomes Key Opinion Leaders to New Advisory Council GlobeNewswire
Apr-03-17 08:51AM  Why Novan (NOVN) Could Be Positioned for a Surge Zacks
Mar-23-17 01:04PM  NOVAN, INC. Financials
12:20PM  The focus for FDA approval: Former Quintiles exec moves to Novan at
12:20PM  The focus for FDA approval: Former Quintiles exec moves to Novan American City Business Journals
02:17AM  Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction GlobeNewswire
Mar-22-17 09:30AM  NOVAN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statem
09:20AM  Novan Reshapes Executive Management Team GlobeNewswire
02:16AM  Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure GlobeNewswire
Mar-21-17 02:16AM  Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis GlobeNewswire
Mar-20-17 02:15PM  Novans loss grew in 2016, but optimistic on development at
08:20AM  Novan reports 4Q loss
08:18AM  NOVAN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:05AM  Novan Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-18-17 09:47AM  New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes GlobeNewswire
Mar-13-17 03:10PM  Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor GlobeNewswire
02:16AM  Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk) GlobeNewswire
Mar-10-17 02:35PM  Company separated from Novan pre-IPO is looking to commercialize later this year at
Mar-09-17 09:04AM  Dr. Nicholas Medendorp, Jr. Named CEO of PhotonMD, Inc. PR Newswire
Mar-06-17 12:18PM  Here's Why Novan Inc. Is Rising Today at Motley Fool +8.76%
10:40AM  Novan stocks trading up after plummeting earlier this year at
09:54AM  Two Biotechs To Watch This Week: Novan Inc (NOVN) And MannKind Corporation (MNKD) at Insider Monkey
06:07AM  NOVAN, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:05AM  Novan Provides Update on SB204 Development Program GlobeNewswire
Mar-03-17 04:05PM  Novan Announces SB204 Program Update Conference Call and Webcast GlobeNewswire +7.58%
Mar-02-17 09:05AM  Novans Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting GlobeNewswire
Mar-01-17 09:05AM  Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference GlobeNewswire
Feb-28-17 08:55AM  Novan (NOVN) Shares March Higher, Can It Continue?
07:45AM  Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting GlobeNewswire
Feb-24-17 07:09AM  Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients GlobeNewswire
Feb-23-17 01:16AM  Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC GlobeNewswire -6.46%
Feb-17-17 05:11PM  Lifshitz & Miller LLP Announces Investigation of Aetna Inc., GenVec, Inc., Ixia, McKesson Corporation, Meridian Bioscience, Inc., Novan, Inc., Regulus Therapeutics Incs., The Southern Company and The Western Union Company PR Newswire
Jan-31-17 03:49PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Novan, Inc. Business Wire -7.73%
Jan-28-17 09:45AM  Is This the Formal Implosion of Novan?
Jan-27-17 01:40PM  Why Novan Inc. Is Imploding Today at Motley Fool -74.01%
01:18PM  NOVAN NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Novan, Inc. To Contact The Firm PR Newswire
12:41PM  NOVAN (NOVN) ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigation of Novan, Inc; Encourages Any Investor to Contact the Firm PR Newswire
11:46AM  INVESTOR ALERT: Investigation of Novan Announced by Holzer & Holzer Business Wire
09:28AM  Novan stock halted on news of 'discordant' statistical significance among two late-stage acne drug trials at MarketWatch
09:05AM  Novan Reports Topline Results from SB204 Phase 3 Pivotal Trials GlobeNewswire
Jan-26-17 03:30PM  The Trump Bump: Raleigh-Durham area stocks that saw the largest gains since Nov. 9 at +5.47%
10:40AM  Anne Whitaker Named CEO of KNOW Bio Respiratory Company PR Newswire
01:16AM  Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report GlobeNewswire
01:11AM  Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery GlobeNewswire
Jan-25-17 01:09AM  Obamacare replacement needs details: Novartis CEO
01:02AM  Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback GlobeNewswire
Jan-17-17 09:09AM  NOVAN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
09:05AM  Novan Licenses SB204 to Sato for Acne in Japan GlobeNewswire
Jan-06-17 01:16AM  Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders GlobeNewswire
Jan-03-17 03:04PM  Will 2017 IPO Market Revive After Dismal 2016? -5.77%
Dec-20-16 01:16AM  Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc. GlobeNewswire -5.22%
Dec-19-16 04:31PM  Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases GlobeNewswire
Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company's product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. Novan, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hodges William LInterim Chief Financial OfficeSep 15Option Exercise6.035,00030,1505,000Sep 18 04:35 PM